Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2021 - 07 - 13 tags : Treatment save search
Madrigal Pharmaceuticals Offers Patients Resmetirom in a Planned Open Label Active Treatment Extension of the Phase 3 MAESTRO-NAFLD-1 Clinical Study
Published: 2021-07-13 (Crawled : 22:00) - globenewswire.com
MDGL | $212.33 -4.47% -4.68% 620K
|
Health Technology
|
| O: 0.85%
H: 0.0%
C: -5.62%
treatment phase 3
MindPath Care Centers Hosts Open House in Charlotte to Introduce FDA-Cleared Deep TMS™ Treatment for Major Depressive Disorder (MDD) and Obsessive-Compulsive Disorder (OCD)
Published: 2021-07-13 (Crawled : 16:00) - globenewswire.com
BWAY | $4.835 0.94% 0.93% 41K
|
Health Technology
|
| O: -1.04%
H: 1.33%
C: -0.11%
treatment fda fda clearance depression major depressive disorder
Petros Pharmaceuticals Completes Pilot Label Comprehension Study to Initiate Process for Stendra® Prescription Erectile Dysfunction Medication to Achieve Designation as an Over-the-Counter Treatment
Published: 2021-07-13 (Crawled : 14:00) - biospace.com/
PTPI | $0.6849 -1.86% -1.9% 150K
|
|
| O: 1.29%
H: 2.39%
C: 1.91%
treatment designation
Moleculin Receives Approval to Extend Dose Escalation in Phase 1/2 European Clinical Trial Evaluating Annamycin for the Treatment of Acute Myeloid Leukemia
Published: 2021-07-13 (Crawled : 13:00) - biospace.com/
MBRX | $4.65 2.8% 2.72% 11K
|
Health Technology
|
| O: 1.12%
H: 3.6%
C: -1.39%
treatment myeloid leukemia europe phase 1 leukemia trial approval phase 2 acute myeloid leukemia
Hoth Therapeutics Announces Positive Confirmatory Results from In Vivo Model of HT-003 Assets as Potential Treatment Against Acne
Published: 2021-07-13 (Crawled : 12:15) - ir.hoththerapeutics.com
HOTH | $1.22 3.39% 3.28% 22K
|
Health Technology
|
| O: 0.67%
H: 0.67%
C: -3.33%
treatment acne potential positive results
Salarius Pharmaceuticals Adds Fox Chase Cancer Center to Ongoing Trial of Seclidemstat as a Treatment for Ewing Sarcoma and FET-Rearranged SarcomasClinical Trial Now Expands to Nine U.S. Trial Sites
Published: 2021-07-13 (Crawled : 12:15) - biospace.com/
SLRX | $0.4848 -2.88% 6.2K
|
Commercial Services
|
| O: 0.93%
H: 0.0%
C: -4.06%
ewing sarcoma treatment ongoing cancer trial seclidemstat
LAVA Therapeutics Announces Treatment of First Patient in Phase 1/2a Clinical Trial of LAVA-051 for Multiple Hematological Malignancies
Published: 2021-07-13 (Crawled : 12:00) - biospace.com/
LVTX | $2.72 -3.89% -4.04% 130K
|
|
| O: 0.82%
H: 1.0%
C: -0.91%
treatment phase 1 trial phase 2 phase 3
Salarius Pharmaceuticals Adds Fox Chase Cancer Center to Ongoing Trial of Seclidemstat as a Treatment for Ewing Sarcoma and FET-Rearranged Sarcomas
Published: 2021-07-13 (Crawled : 12:00) - globenewswire.com
SLRX | $0.4848 -2.88% 6.2K
|
Commercial Services
|
| O: 0.93%
H: 0.0%
C: -4.06%
ewing sarcoma treatment ongoing cancer trial seclidemstat
Relief Therapeutics Reports that Collaboration Partner, NRx Pharmaceuticals, and Quantum Leap Announce Treatment of Severely Ill COVID-19 Patients with Aviptadil in the I-SPY COVID Trial
Published: 2021-07-13 (Crawled : 09:00) - biospace.com/
NRXP 2 d | $3.08 1.99% 1.95% 230K
|
Manufacturing
|
| O: 6.84%
H: 11.25%
C: 5.04%
covid treatment collaboration trial aviptadil
MEDIA ADVISORY: Ultragenyx Announces Mepsevii® (vestronidase alfa) Receives Reimbursement Approval for Treatment of Mucopolysaccharidosis VII in Spain
Published: 2021-07-13 (Crawled : 08:00) - globenewswire.com
RARE | News F | $42.37 -2.33% -2.38% 680K
|
Health Technology
|
| O: -0.16%
H: 2.26%
C: -4.01%
media treatment approval
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.